$7.79 0.01 (+0.13%)
11/25/2009 4:00 PM

ViroPharma, Inc. (VPHM)

CAPS Rating: 5 out of 5

A biopharmaceutical company dedicated to the development and commercialization of products that address serious infectious diseases, with a focus on products used by physician specialists or in hospital settings.

Results 1 - 1 of 1

Recs

1
Member Avatar rmbashir (< 20) Submitted: 9/26/2006 6:02:09 AM : Underperform Start Price: $12.58 VPHM Score: +27.31

NO SOLID PHASE 3 TRIALS.
HAVE MANY FAILURES IN THE PIPELINE; ALOT OF COMPETETION FOR HEP C, INCLUDING INGENIX AND SCHERING WITH PROTEASE INHIBITORS COMING OUT. NEED NEW BLOOD COARSING THROUGH ITS VEINS OR COULD SETTLE IN AT 11-13.

Report this Post 0 Comments | Reply | Permalink
Results 1 - 1 of 1

Featured Broker Partners